Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
524actual
Sites
48
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-12 | actual | When the study began enrolling |
| Primary completion | 2025-03-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-01 | actual | The whole study's end, after follow-up |
| First posted | 2023-05-16 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-11 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: Atogepant — also filed as Qulipta
- Drug: Placebo for Atogepant
Primary outcomes
what the primary-completion date above is the date OFChange From Baseline in Mean Monthly Migraine Days
measured Up to Week 12
Number of Participants Experiencing With Adverse Events (AEs)
measured Up to Week 12
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-07-18 · 2.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-10-22 · 587 KB · SAP_001.pdf
Publications
- PMID 41002192 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed